Status:
COMPLETED
Bacterial and Fungal Microbiota of Patients With Severe Viral Pneumonia With COVID-19
Lead Sponsor:
University Hospital, Lille
Conditions:
Sars-CoV2
Eligibility:
All Genders
18+ years
Brief Summary
Observational pilot single-center study aiming to determine the microbiota of critically ill patients infected with SARS-CoV-2. COVID-19 patients will be compared to historical critically ill controls...
Detailed Description
Observational pilot single-center study aiming to determine the microbiota of critically ill patients infected with SARS-CoV-2. COVID-19 patients will be compared to historical critically ill controls...
Eligibility Criteria
Inclusion
- For the Covid-19 Group: with a confirmed severe lung infection with CoV2-SARS-Cov2 admitted to the ICU.
- For the Control Group:
- Historic cohort of non SARS -CoV2-infected adults admitted to the ICU (between March and October 2019),
- that was investigated for fecal microbiota in a previous study (control patients in a fecal microbiota study in patients included in the SEAT study).
Exclusion
- For the Covid-19 group:
- Lack of coverage Patients who received antibiotic therapy within 6 weeks prior to Covid-19 symptomatology,
- Pregnant women,
- Severe immunosuppression: Neutropenia \< 0.5 G/L, Chemotherapy \< 6 months, Bone marrow transplant recipients, HIV with CD4+ lymphocytes \< 0.4 G/L
- Impossible to perform bronchoalveolar lavage,
- Non-socially insured,
- Refusal to participate in the social study
Key Trial Info
Start Date :
May 8 2020
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
October 23 2020
Estimated Enrollment :
34 Patients enrolled
Trial Details
Trial ID
NCT04359706
Start Date
May 8 2020
End Date
October 23 2020
Last Update
October 17 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hôpital Roger Salengro, CHU Lille
Lille, France, 59037